# OnCo record synthekine (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/synthekine/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "synthekine" ;
  schema:name "Synthekine"@en ;
  schema:alternateName "Synthekine, Inc."@en ;
  schema:description "A US company that re-engineers cytokines, the immune system's chemical messengers, so they act on helpful immune cells and spare the ones that cause side effects. Its lead drug is in a Phase 2 trial for a type of lung cancer."@en ;
  schema:url <https://onco.cc/companies/synthekine/>, <https://www.synthekine.com/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://www.synthekine.com/>, <https://www.synthekine.com/our-pipeline/>, <https://www.synthekine.com/about-us/>, <https://clinicaltrials.gov/study/NCT05098132>, <https://www.racap.com/portfolio/synthekine> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/cytokine-therapy/> ;
  onco:targets <https://onco.cc/targets/cd25/>, <https://onco.cc/targets/il2rb/> ;
  onco:drugs <https://onco.cc/drugs/stk-012/> ;
  onco:trials <https://onco.cc/trials/nct05098132/> .